Scholar Rock Holding (SRRK) Change in Receivables (2020)
Scholar Rock Holding (SRRK) recorded quarterly Change in Receivables of -$25.0 million in Q1 2020.
Scholar Rock Holding (SRRK) Change in Receivables (2020) Analysis & Trends
Scholar Rock Holding's Change in Receivables history runs 1 years deep, the most recent figure standing at -$25.0 million for Q1 2020.
- In Q1 2020, Change in Receivables changed N/A year-over-year to -$25.0 million; the TTM figure through Dec 2020 stood at -$25.0 million (changed N/A YoY), while the FY2020 annual figure was -$25.0 million, down 200.0% from the prior year.
- Change in Receivables was -$25.0 million for Q1 2020 at Scholar Rock Holding.
- In the past five years, Change in Receivables ranged from a high of -$25.0 million in Q1 2020 to a low of -$25.0 million in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Scholar Rock Holding | 6.03 Bn | 5.55 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -25.00 Mn |
| Mar 31, 2020 | -25.00 Mn |